Cabaletta Bio, Inc. develops engineered T cell therapies for autoimmune diseases as a late-stage clinical biotechnology company. Its CABA platform includes the CARTA strategy, and its lead investigational therapy, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy evaluated through the RESET clinical development program across rheumatology, neurology and dermatology.
Recurring company updates cover rese-cel clinical and translational data, trial-program presentations, manufacturing scale-up, and supply arrangements using automated cell-therapy production platforms. News also includes financial results, business updates, conference participation, shareholder voting matters, capital-structure disclosures, and regulatory disclosures tied to Cabaletta Bio’s autoimmune cell-therapy pipeline.
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. CEO Steven Nichtberger will present at two investor conferences on January 11, 2021. The presentations will be available via webcast on the company's website, starting at 6:00 a.m. and 7:00 a.m. ET respectively. The company's approach utilizes Chimeric AutoAntibody Receptor T cells, targeting specific autoantibody-producing B cells. Its leading candidate, DSG3-CAART, is in a phase 1 clinical trial for mucosal pemphigus vulgaris, with Fast Track Designation from the FDA.
Cabaletta Bio, Inc. (Nasdaq: CABA) achieved a significant milestone by infusing the first patient with its DSG3-CAART therapy during the DesCAARTes™ Phase 1 clinical trial. This trial aims to treat mucosal-dominant pemphigus vulgaris (mPV) and explores CAAR T cell technology for autoimmune diseases. DSG3-CAART could provide a more targeted and durable treatment option compared to current therapies that often induce broad immunosuppression. The trial will assess safety, tolerability, and early efficacy signs with an expected enrollment of 30 subjects across multiple sites in the U.S.
Cabaletta Bio, focused on engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in December 2020. Steven Nichtberger, M.D., the CEO, will partake in a pre-recorded chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and a live discussion at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 3. The company’s pipeline includes DSG3-CAART, which targets mucosal pemphigus vulgaris and has received FDA Fast Track Designation. Webcast replays will be accessible for 90 days on their website.
Cabaletta Bio, Inc. (CABA) reported its Q3 2020 financial results, highlighting progress in its clinical programs. The company is actively enrolling patients in its Phase 1 trial for DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, expecting to report acute safety data in the first half of 2021. Q3 R&D expenses rose to $5.7 million from $3.2 million in Q3 2019, and G&A expenses increased to $2.8 million from $1.8 million. As of September 30, 2020, cash and equivalents stood at $118.1 million, down from $136.2 million at year-end 2019, enough to fund operations through Q3 2022.
Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies for B cell-mediated autoimmune diseases, announced that CEO Steven Nichtberger will speak at three investor conferences in October 2020. The presentations include:
- Stifel 2020 Immunology and Inflammation Virtual Summit on October 1 at 3:00 p.m. ET.
- Jefferies Virtual Cell Therapy Summit on October 5 at 8:30 a.m. ET.
- Chardan 4th Annual Genetic Medicines Conference on October 6 at 11:30 a.m. ET.
Webcasts will be available on the company’s website.
Cabaletta Bio, a clinical-stage biotechnology company, announced that Dr. Steven Nichtberger will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast of the event will be available on their website, with a replay accessible for 90 days. The company is focused on engineered T cell therapies for B cell-mediated autoimmune diseases, leveraging their Cabaletta Approach to selectively eliminate specific B cells while preserving normal ones. Their lead candidate, DSG3-CAART, targets mucosal pemphigus vulgaris.
Cabaletta Bio, Inc. (CABA) announced promising in vivo preclinical data for its Chimeric AutoAntibody Receptor T cells targeting MuSK-associated myasthenia gravis. Presenting at AAN 2020, the data showed the T cells effectively recognized and eliminated B cells expressing anti-MuSK antibodies, with no harm to normal B cells. The study supports plans for Investigational New Drug (IND)-enabling studies in 2020, addressing a significant unmet need in MuSK MG treatment.
Cabaletta Bio, Inc. (CABA) announced its Q1 2020 financial results, highlighting a significant milestone with the FDA granting Fast Track Designation for its lead candidate, DSG3-CAART, aimed at treating mucosal pemphigus vulgaris (mPV). The Phase 1 DesCAARTes™ trial is ready to launch pending COVID-19 restrictions. R&D expenses were $4.6 million, while G&A expenses totaled $3.3 million. Cash reserves stood at $131 million, projected to support operations through Q3 2022.